Related Experiment Video

Updated: May 18, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

The genesis of Zelboraf: targeting mutant B-Raf in melanoma

Matthew J Davis1, Joseph Schlessinger

  • 1Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA.

The Journal of Cell Biology
|October 3, 2012
PubMed

Insights

Targeted therapy Zelboraf effectively treats metastatic melanoma by inhibiting the oncogenic B-Raf kinase, a key player in the Ras/MAPK pathway found in about half of melanoma cases.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • The Ras/MAPK signaling pathway is crucial for cell regulation.
  • Mutations in B-Raf kinase are common drivers in melanoma and other cancers.
  • Constitutive activation of B-Raf promotes uncontrolled cell proliferation.

Purpose of the Study:

  • To develop a targeted inhibitor for oncogenic B-Raf.
  • To evaluate the efficacy of Zelboraf in treating B-Raf-mutated cancers.
  • To leverage structure-guided drug design for therapeutic advancement.

Main Methods:

  • Utilized a structure-guided drug discovery approach.
  • Developed Zelboraf as a specific inhibitor of mutated B-Raf.
  • Clinical trials assessed Zelboraf in metastatic melanoma patients.

Main Results:

  • Zelboraf demonstrated successful clinical application.
  • The drug specifically targets and inhibits constitutively active B-Raf.
  • Treatment showed efficacy in patients with B-Raf mutations.

Conclusions:

  • Targeted inhibition of oncogenic B-Raf is a viable therapeutic strategy.
  • Zelboraf represents a successful outcome of structure-guided drug discovery.
  • Personalized medicine approaches targeting specific mutations are effective in cancer treatment.

More Related Videos

Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model10:23

Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model

Published on: November 13, 2012

Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells06:44

Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells

Published on: March 1, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...